-
03
2025
Caliway’s CBL-514 Phase 2 Study (CBL-0202) Accepted for Publication in the Aesthetic Surgery Journal
CBL-514 Phase 2 study (CBL-0202) has been accepted for publication in Aesthetic Surgery Journal (ASJ).
-
02
2025
2025.02.12 -
Caliway Biopharmaceuticals Added to MSCI World Small Cap Index, Reinforcing Global Standing
Caliway has been added to the MSCI World Small Cap Index, as announced today by MSCI (Morgan Stanley Capital International) in its latest quarterly review.
-
02
2025
2025.02.09 -
Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints
Caliway announced today that CBL-514’s second Phase 2b clinical study (CBL-0205) successfully met its primary and all critical secondary efficacy endpoints.
-
02
2025
2025.02.03 -
Caliway Presented CBL-0204 Phase 2b Study Results of CBL-514 at IMCAS 2025 in Paris
Innovative Non-Surgical Fat Reduction Treatment Gains International Attention
